Cerulean Pharma Inc. Closes $24 Million in Series C Financing
Cerulean Pharma Inc. closed a $24 million Series C financing. Lilly Ventures led the round, with participation from all existing investors including Polaris Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners. Lilly’s Venture Partner Steve Hall joined the board of the Cambridge, Mass.-based designer and developer of nanopharmaceuticals. Cerulean plans to use the capital to advance its CRLX101development candidate into a randomized Phase II trial as a non-small cell lung cancer drug.
15 November 2010•4 mins read
